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Abstract
Introduction Mammary tumorigenesis is associated with the
increased expression of several proteins in the focal adhesion
complex, including focal adhesion kinase (FAK) and various
integrins. Aberrant expression of these molecules occurs
concomitant with the conversion of TGF-β function from a tumor
suppressor to a tumor promoter. We previously showed that
interaction between β3 integrin and TβR-II facilitates TGF-β-
mediated oncogenic signaling, epithelial-mesenchymal
transition (EMT), and metastasis. However, the molecular
mechanisms by which the focal adhesion complex contributes
to β3 integrin:TβR-II signaling and the oncogenic conversion of
TGF-β remain poorly understood.
Methods FAK expression and activity were inhibited in normal
and malignant mammary epithelial cells (MECs) either
genetically by using lentiviral-mediated delivery of shRNAs
against FAK, or pharmacologically through in vitro and in vivo
use of the FAK inhibitors, PF-562271 and PF-573228. Altered
Smad2/3 and p38 MAPK activation, migration, EMT, and
invasion in response to TGF-β1 were monitored in FAK-
manipulated cells. TβR-II expression was increased in
metastatic breast cancer cells by retroviral transduction, and the
metastasis of FAK- and TβR-II-manipulated tumors was
monitored by using bioluminescent imaging.
Results TGF-β stimulation of MECs stabilized and activated
FAK in a β3 integrin- and Src-dependent manner. Furthermore,
by using the human MCF10A breast cancer progression model,
we showed that increased FAK expression in metastatic breast
cancer cells mirrored the acquisition of enhanced activation of
p38 MAPK by TGF-β. Administering FAK inhibitors or rendering
metastatic breast cancer cells FAK deficient abrogated the
interaction between β3 integrin and TβR-II, thereby preventing
TGF-β from (a) activating p38 MAPK; (b) stimulating MEC
invasion, migration, and EMT; and (c) inducing early primary
tumor dissemination to the lungs. Finally, in contrast to FAK
depletion, adjuvant FAK chemotherapy of mammary tumors
decreased their growth in part by diminished macrophage tumor
infiltration.
Conclusions Our studies identify an essential function for FAK
in mediating the interaction between β3 integrin and TβR-II, and
thus in facilitating the oncogenic conversion of TGF-β required
for mammary tumor metastasis. Furthermore, this study
establishes chemotherapeutic targeting of FAK as an effective,
two-pronged approach in preventing tumor progression both by
decreasing innate immune cell infiltration, and by inhibiting early
TGF-β-dependent metastasis.
Introduction
Invasion and metastasis are the most lethal characteristics of
breast cancer [1,2]. Transforming growth factor (TGF)-β is a
powerful suppressor of mammary tumorigenesis through its
ability to repress mammary epithelial cell (MEC) proliferation,
as well as through its creation of cellular microenvironments
that inhibit MEC motility, invasion, and metastasis. During
breast cancer progression, the tumor-suppressing function of
TGF-β is frequently subverted, thus transforming TGF-β from
a suppressor of breast cancer formation to a promoter of its
growth and metastasis [2-4]. Indeed, how TGF-β both sup-
presses and promotes tumorigenesis remains an unknown
and fundamental question that directly affects the ability of sci-
ence and medicine to target effectively the TGF-β signalingPage 1 of 16
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phering this paradox remains the most important question con-
cerning the biologic and pathologic actions of this
multifunctional cytokine [5].
FAK is a ubiquitously expressed protein tyrosine kinase (PTK)
whose amino acid sequence is about 90% homologous
between humans, chickens, mice, and frogs [6]. An essential
function for FAK during mammalian development is evident in
the lethality of FAK-deficient embryos at E8.5 [7], presumably
due to an indispensable role of FAK in regulating cell migration
[8], proliferation, and survival [9]. Along these lines, aberrant
FAK expression or activity also supports carcinoma cell metas-
tasis by enhancing these same cellular processes in cancer
cells [10], and possibly in cancer stem cells [11], to support
tumor angiogenesis [12]. Although it remains to be deter-
mined whether altered expression or subcellular localization of
FAK possesses true prognostic value to cancer patients,
recent studies do provide strong evidence associating
increased FAK expression with the development and progres-
sion of mammary carcinomas [10,12-15]. To this end, small-
molecule inhibitors of FAK have recently been developed and
show potent efficacy to inhibit FAK PTK activity specifically, as
well as to decrease the growth of subcutaneous tumor
xenografts [13,16]. Despite these recent advances, the onco-
genic signaling modules targeted by aberrant FAK expression
and activity in developing and progressing breast cancers, and
their potential role in regulating the activity and composition of
associated tumor stroma remain to be fully defined.
We recently identified a critical αvβ3 integrin:TβR-II:Src:Grb2
signaling axis that mediates TGF-β stimulation of MAP kinases
in normal and malignant MECs, leading to their acquisition of
epithelial-mesenchymal transition (EMT), invasive, and meta-
static phenotypes both in vitro and in vivo. Activation of this
oncogenic signaling axis by TGF-β requires β3 integrin to form
complexes with TβR-II [17-19]; however, whether the β3
integrin/TβR-II interaction is direct or mediated via an acces-
sory protein remains unknown. The present study addresses
this important question, as well as establishes the therapeutic
effectiveness of inhibiting FAK PTK activity in a TGF-β-driven
model of breast cancer metastasis.
Materials and methods
Cell lines and reagents
Normal murine NMuMG and metastatic 4T1 cells were
obtained from ATCC (Manassas, VA) and cultured as
described previously [18]. 4T1 cells were engineered to
express stably firefly luciferase by their transfection with
pNifty-CMV-luciferase [20] and selection with Zeocin (500
μg/ml; Invitrogen, Carlsbad, CA). NMuMG cells expressing
WT or the nonfunctional mutant D119A-β3 integrin were con-
structed by retroviral transduction, as described previously
[19]. The MCF10A cell derivates T1k, Ca1h, and Ca1a were
cultured in DMEM/F12 supplemented with 5% horse serum.
The construction of NMuMG and 4T1 cells lacking FAK was
accomplished by their lentiviral-mediated transduction with a
scrambled (i.e., nonsilencing shRNA) or verified FAK-specific
shRNA sequence encoded in pLentilox3.7-puro [15]. In brief,
human 293T cells were transiently transfected with lentiviral
packaging vectors (i.e., pMD2.G, pRRE, pRSV, and pLentiLox
3.7) according to standard protocols [21], and 48 h after
transfection, the resulting conditioned medium was collected,
filtered, and mixed with polybrene (8 μg/ml). Target cells were
incubated in viral-containing supernatants for 48 h, and cells
expressing nonsilencing or FAK-specific shRNAs were iso-
lated by puromycin selection (5 μg/ml) for 14 days. Afterward,
puromycin-resistant NMuMG and 4T1 cells were assayed for
FAK-deficiency by immunoblotting with anti-FAK antibodies,
as described later.
Immunoblot and immunoprecipitation assays
For FAK immunoblots, β3 integrin-expressing NMuMG cells
were trypsinized, pelleted, and maintained in a nonadherent
state for 4 h in serum-reduced media (0.5%). Afterward, the
cells either were immediately harvested or were replated in the
absence or presence of TGF-β1 (5 ng/ml) for an additional 4 h,
at which point they were harvested to detect differences in
FAK phosphorylation and expression by immunoblotting (see
later). Whole-cell extracts prepared from normal and malignant
MECs were immunoprecipitated with antibodies against TβR-
II, Grb2, and β3 integrin (Santa Cruz Biotechnology, Santa
Cruz, CA), and the resulting immunocomplexes were immuno-
blotted various antibodies listed later [19]. Where specified,
4T1 cells were incubated for 18 h in the absence or presence
of the FAK inhibitors, PF-562271 or PF-573228 (Pfizer, Inc.,
New York, NY) at the indicated concentrations before immu-
noprecipitation of β3 integrin. NMuMG cells also were incu-
bated in serum-reduced media (0.5% FBS) supplemented
with TGF-β1 (5 ng/ml) for 18 h in the absence or presence of
the Src inhibitor, PP2 (10 μg/ml; Calbiochem, Temecula, CA).
For all cell-signaling experiments, 4T1 or NMuMG cells were
serum starved (0 FBS) or deprived (0.5% FBS), respectively,
for 6 h before TGF-β1 stimulation (5 ng/ml). Control and FAK-
deficient 4T1 cells were incubated for up to 48 hours with
TGF-β1 (5 ng/ml) and detergent-solubilized whole-cell extracts
were prepared and immunoblotted for E-cadherin (E-Cad; BD
Biosciences, San Jose, CA). Last, 4T1 cells were incubated
with TGF-β1 (5 ng/ml) for 24 h in serum-free medium, and the
resulting conditioned medium was precipitated with 0.01%
sodium deoxycholate/6.25% trichloracetic acid and immunob-
lotted for plasminogen activator inhibitor-1 (PAI-1; Santa Cruz
Biotechnology).
Cell extracts were prepared by harvesting NMuMG and 4T1
cells on ice in 3-D RIPA buffer (50 mM Tris, 150 mM NaCl, 6
mM sodium deoxycholate, 1.0% NP-40, 0.1% SDS, pH 7.4)
supplemented with protease inhibitor cocktail (Sigma, St.
Louis, MO) and phosphatase inhibitors (10 mM sodium
orthovanadate, 40 mM β-glycerophosphate, 20 mM NaF), andPage 2 of 16
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immunoblotting with the following primary antibodies (dilu-
tion): (a) anti-phospho-Y397-FAK (1:1000; Cell Signaling,
Danvers, MA); (b) anti-phospho-Y577-FAK (1:1000; Cell Sig-
naling); (c) anti-phospho-Y925-FAK (1:1,000; Cell Signaling);
(d) anti-phospho-p38 MAPK (1:500; Cell Signaling); (e) anti-
phospho-Smad2 (1:1,000; Cell Signaling); (f) anti-phospho-
Smad3 (1:500; Cell Signaling); (g) anti-E-cadherin (1:2,500
BD Biosciences); (h) anti-PAI-1 (1:1,000; Santa Cruz Bio-
technology); (i) anti-FAK (1:1,000; Santa Cruz Biotechnol-
ogy); (j) anti-β-actin (1:1,000; Santa Cruz Biotechnology); (k)
anti-p38 MAPK (1:1,000; Santa Cruz Biotechnology); (l) anti-
Smad2/3 (1:1,000; Cell signaling); (m) anti-phospho-Y416-
Src (1:1,000; Cell Signaling); and (n) anti-Src (1:1,000, Cell
Signaling).
Cell migration and invasion assays
Confluent NMuMG cell cultures were wounded with a micro-
pipette tip (200 μl) and immediately placed in 1% serum-con-
taining medium supplemented with or without TGF-β1 (5 ng/
ml) or the TβR-I inhibitor, SB-431542 (10 μM; Sigma). Bright-
field images of wounded monolayers were obtained immedi-
ately after wounding (T0) and at various times thereafter as
indicated. The extent of wound closure was quantified by
obtaining three wound measurements for each of three ran-
dom fields (x100) per wound, and all wound conditions were
performed in triplicate. Measurements were taken by using the
SlideBook Imaging Software (Intelligent Imaging Innovations,
Inc., Denver, CO). The ability of TGF-β1 (5 ng/ml) to alter the
invasion of 4T1 cells (50,000 cells/well) was analyzed by
using a modified Boyden Chamber assay, as described previ-
ously [19].
Luminescent reporter gene assays
Alterations in gene expression regulated by TGF-β were
assessed by using a reporter gene assay that monitored
changes in luciferase expression driven by the synthetic SBE
(Smad-binding element) promoter, as described previously
[22]. In brief, NMuMG cells (25,000 to 30,000 cells/well)
were allowed to adhere overnight to 24-well plates. The follow-
ing morning, the cells were transiently transfected by overnight
exposure to LT1-liposomes (Mirus, Madison, WI) that con-
tained 300 ng/well of pSBE-luciferase cDNA and 50 ng/well
of CMV-β-gal cDNA, which was used to control for differences
in transfection efficiency. Afterward, the cells were washed
twice with PBS and stimulated overnight with TGF-β1 (5 ng/
ml) in serum-deprived (0.5% FBS) media. Upon completion of
agonist stimulation, firefly luciferase and β-gal activities
present in detergent-solubilized cell extracts were determined.
In addition, 4T1-luciferase cells that stably expressed firefly
luciferase under control of the CMV promoter were cultured
into 96-well plates at a density of 10,000 cells/well and sub-
sequently were transiently transfected with an SBE reporter
plasmid that drove expression of renilla luciferase. The trans-
fectants were stimulated with TGF-β1 as described previously,
and subsequently were processed for the determination of
renilla and firefly luciferase by using the Dual-Glo Assay Sys-
tem (Promega, Madison, WI).
Real-time PCR analyses
NMuMG and 4T1 cells were stimulated with TGF-β1 (5 ng/ml)
for 24 h, and total RNA was isolated by using the RNeasy Plus
Kit (Qiagen, Valencia, CA). Afterward, total RNA was reverse
transcribed by using the iScript cDNA Synthesis System (Bio-
Rad, Hercules, CA), and semiquantitative real-time PCR was
conducted by using iQ SYBR Green (BioRad) according to
the manufacture's recommendations and as described previ-
ously [23]. In all cases, differences in RNA concentration were
controlled by normalizing individual gene signals to their corre-
sponding GAPDH RNA signals. The oligonucleotide primer
pairs used are provided in Additional data file 1.
Immunofluorescent analyses
NMuMG cells (25,000 cells/well) were allowed to adhere
overnight to glass coverslips in a 24-well plate. Afterward, the
cells were washed extensively in PBS and immediately stimu-
lated with TGF-β1 (5 ng/ml) in serum-deprived (0.5% FBS)
media for 18 h. Upon completion of agonist stimulation, the
cells were (a) fixed in 4% paraformaldehyde; (b) permeablized
in 0.1% Triton X-100; (c) stained with phospho-Y925 FAK
antibodies according to the manufacture's instructions (Cell
Signaling); and (d) visualized by using FITC-labeled donkey
anti-rabbit secondary antibodies (Jackson ImmunoResearch,
West Grove, PA). The actin cytoskeleton was visualized by
using TRITC-conjugated phalloidin (0.25 μM; Invitrogen) as
described previously [19].
Tumor growth, bioluminescent imaging, and 
immunohistochemical analyses
Control or various 4T1 derivatives engineered to express firefly
luciferase stably were resuspended in sterile PBS (50 μl) and
injected orthotopically into the mammary fat-pads (0.5 to 1.0
× 104 cells/injection) of 6-week-old female Balb/C mice (Jack-
son Labs, Bar Harbor, ME). Primary tumor growth and metas-
tasis development was assessed by using digital calipers
(Fisher Scientific, Waltham, MA), and by weekly biolumines-
cent imaging on a Xenogen IVIS-200 (Caliper Life Sciences,
Hopkinton, MA). Tumor volumes were calculated by using the
following equation:
where "x" is the tumor width and "y" is the tumor length. Finally,
serial histologic sections of control and FAK-deficient 4T1
tumors removed after the study were stained with phospho-
specific antibodies against p38 MAPK and Smad2 and coun-
terstained with hematoxylin, as previously described [17].
Where indicated, mice were treated daily with PF-562271 (50
mg/kg) or vehicle (5% gelucire 44/14; Gattefosse, Saint
Priest Cedex, France) by oral gavage. Histologic sections from
Tumor volume x y= ( )( )( . )2 0 5Page 3 of 16
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rophage marker (IHC Tech, Aurora, CO), or with phospho-
specific antibodies against Y397-FAK, as described previ-
ously [17]. All animal studies were performed in accordance
with the animal protocol procedures approved by the Institu-
tional Animal Care and Use Committee of University of
Colorado.
Statistical analysis
Statistical values were defined by using an unpaired Student's
t-test; a P value <0.05 was considered significant. P values for
all experiments analyzed are indicated.
Results
TGF-β-stimulated FAK activation and stabilization is 
dependent on Src and β3 integrin
NMuMG cells exhibit several distinct morphologic features in
response to TGF-β, most notably a dramatic reorganization of
the actin cytoskeleton [24]. Figure 1a shows that phosphor-
ylated FAK localized primarily to the periphery in quiescent
NMuMG cells, producing a staining pattern very similar to that
of F-actin, which was visualized with phalloidin staining (Figure
1a). However, upon TGF-β1 stimulation, phosphorylated FAK
underwent a dramatic reorganization and localized primarily at
the end of actin stress fibers (Figure 1a; overlay). Accordingly,
immunoblotting NMuMG cell extracts with a panel of phospho-
specific FAK antibodies showed that TGF-β stimulation dra-
matically increased the phosphorylation of FAK (Figure 1b).
Figure 1b also shows that TGF-β stimulation increased FAK
protein levels in NMuMG cells and induced an impressive
upregulation of β3 integrin [19]. Both the increase in FAK
phosphorylation and expression, as well as the increase in β3
integrin expression were wholly dependent on Src activity,
because treating these same cells with the Src inhibitor, PP2,
abrogated FAK phosphorylation at the Src-dependent sites
(Y577 and Y925) and prevented TGF-β1-induced expression
of FAK and β3 integrin (Figure 1b). Furthermore, in contrast to
control (i.e., GFP) and WT-β3 integrin-expressing NMuMG
cells, those engineered to express a signaling-deficient mutant
of β3 integrin, D119A-β3, exhibited drastically reduced mainte-
nance of FAK protein levels and phosphorylation in response
to nonadherent conditions (Figure 1c). To more thoroughly
investigate the role of β3 integrin in TGF-β-mediated stabiliza-
tion and phosphorylation of FAK, nonadherent NMuMG cells
were replated in the absence or presence of TGF-β1 before
analyzing FAK expression and phosphorylation by immunob-
lotting. As shown in Figure 1d, treatment of control (i.e., GFP)
and WT-β3 integrin-expressing NMuMG cells with TGF-β1
stimulated increased FAK phosphorylation (Figure 1d). In stark
contrast, TGF-β treatment of D119A-β3 integrin-expressing
NMuMG cells actually decreased their expression and phos-
phorylation of FAK (Figure 1d). Finally, we conducted real-time
PCR for FAK in control (i.e., GFP), WT-β3, D119A-β3 integrin-
expressing NMuMG cells. As shown in Figure 1e, chronic
TGF-β stimulation (i.e., 24 h) had no effect on FAK mRNA lev-
els in control or WT-β3 integrin-expressing NMuMG cells;
however, these same experimental conditions did increase
FAK mRNA expression in D119A-β3 NMuMG cells. These
data strongly suggest that (a) upregulated β3 integrin expres-
sion is required to stabilize FAK protein levels upon TGF-β
stimulation, and (b) activated β3 integrin signaling acts as a
negative-feedback mechanism governing FAK transcription.
Along these lines, our use of oligonucleotide sequences that
specifically amplified murine β3 integrin sequences, not that of
recombinant human WT or D119A β3 integrin sequences,
showed that NMuMG cells engineered to overexpress WT-β3
integrin failed to upregulate endogenous murine β3 integrin
transcripts in response to TGF-β stimulation (Figure 1f). Thus,
these findings provide the first evidence that the stability and
extent of FAK phosphorylation induced by TGF-β is critically
dependent on its ability to upregulate functional β3 integrin,
and that both of these events require the activity of Src kinase.
These data also suggest that FAK may play a critical function
with β3 integrin and Src [19] in facilitating TGF-β signaling and
function in MECs.
FAK is critically involved in TGF-β-induced p38 MAPK 
activation and mammary epithelial cell migration
To assess the role of FAK in mediating downstream TGF-β sig-
naling events, we next used shRNAs to deplete stably the
expression of FAK in NMuMG cells (Figure 2a). As shown in
Figure 2a and 2b, FAK-deficiency had no effect on canonical
Smad2/3 activity stimulated by TGF-β, but did markedly dis-
rupt the coupling of TGF-β to the noncanonical p38 MAPK
pathway. Furthermore, the quiescent architecture of the actin
cytoskeleton, as well as TGF-β-induced actin stress fibers
were severely disrupted upon FAK depletion (Figure 2c). We
also examined the impact of FAK deficiency on the ability of
TGF-β to stimulate MEC migration. To do so, confluent monol-
ayers of control or FAK-deficient NMuMG cells were wounded
with a micropipette tip, and the extent of MEC migration into
the denuded area was measured at various times thereafter.
Stimulating FAK-deficient NMuMG cells with TGF-β1
enhanced their wound-healing response [25], although at a
significantly reduced rate as compared with control (i.e.,
scrambled shRNA) NMuMG cells (Figure 2d), suggesting that
FAK plays a critical role in TGF-β-induced MEC migration.
Accordingly, administration of the TβR-I inhibitor, SB-431542,
inhibited control NMuMG cell wound closure, thereby identify-
ing a role for autocrine TGF-β signaling in mediating the clo-
sure of MEC wounds. Interestingly, FAK-deficient NMuMG
cells were refractory to administration of the TβR-I inhibitor
(Figure 2d), suggesting that these cells have adapted a less-
efficient mechanism of migration that is no longer dependent
on the activities of TGF-β and FAK. Finally, as wound closure
is driven by both cell migration and proliferation, the
decreased growth rate of FAK-deficient cells (see Additional
data file 2a) may contribute to their reduced wound-healing
response. However, this does not appear to be the case in
NMuMG cells, as control and FAK-deficient cells exhibitPage 4 of 16
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Figure 1
Transforming growth factor (TGF)-β-stimulated focal adhesion kinase (FAK) phosphorylation depends on Src and β3 integrin. (a) Fluorescently 
labeled phalloidin (red) and phosphorylated Y925-FAK (green) staining in quiescent (NS) NMuMG cells showed normal cortical actin distribution 
that colocalized with phosphorylated FAK at cell-cell junctions and borders. Administering TGF-β1 (5 ng/ml) for 18 hours promoted F-actin stress 
fiber formation, and reorganized phosphorylated FAK. DAPI counterstaining, shown in blue (overlay). Data are representative images from a single 
experiment that was repeated 3 times. (b) Immunoblot analysis of cell extracts prepared from NMuMG cells stimulated with TGF-β1 as in (a) showed 
that TGF-β treatment induced the phosphorylation of FAK at positions Y397, Y577, and Y925. Total FAK protein levels also were increased. Admin-
istration of the Src inhibitor, PP2 (10 μg/ml) for the duration of the TGF-β1 treatment (18 hours), prevented the phosphorylation of FAK at Y577 and 
Y925, but not at its autophosphorylation site, Y397. In addition, PP2 treatment prevented the induction of β3 integrin expression in NMuMG cells 
stimulated with TGF-β1. Differences in protein loading were monitored by reprobing stripped membranes with antibodies against β-actin. Data are 
representative images from a single experiment that was repeated 3 times. (c) FAK phosphorylation and its overall expression was decreased in non-
adherent NMuMG cells (4 hours) expressing mutant β3 integrin (D119A), but not its wild-type counterpart (β3-WT). Protein loading was monitored 
by reprobing stripped membranes with antibodies against β-actin. Data are representative images from a single experiment that was repeated 3 
times. (d) NMuMG cells were treated as in (c) and then replated for 4 hours in the absence or presence of TGF-β1 (5 ng/ml) before analyzing FAK 
phosphorylation and expression. Protein loading was monitored by reprobing stripped membranes with antibodies against β-actin. Data are repre-
sentative images from a single experiment that was repeated twice with identical results. (e, f) Polyclonal populations of control (i.e., GFP), WT-β3 
integrin (β3-WT)-, or D119A-β3 integrin (β3-D119A)-expressing NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for 24 hours, and total RNA 
was isolated and analyzed with semiquantitative real-time polymerase chain reaction (PCR) to monitor FAK (e) and murine β3 integrin (f) expression. 
Data are expressed as the mean (± SEM; n = 3) relative FAK and β3 integrin transcript levels measured in response to TGF-β1, as compared with 
their unstimulated counterparts. (*P < 0.05).
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ng/ml; see Additional data file 2b), which indicates that the dif-
ference in wound healing between control and FAK-deficient
cells reflects alterations in their ability to migrate, not to prolif-
erate (Figure 2d). Taken together, these data strongly suggest
that FAK is directly involved in mediating TGF-β-induced MEC
migration.
FAK is required for oncogenic signaling by TGF-β
Imbalances between canonical and noncanonical TGF-β sign-
aling contribute to mammary tumorigenesis [4]. We illustrated
this shift in TGF-β signaling by using the human MCF10A
breast cancer progression model that consists of indolent
(T1K), malignant nonmetastatic (Ca1h), and malignant meta-
static (Ca1a) cells [26,27]. With this model system, we
observed an enhanced ability of TGF-β to activate specifically
p38 MAPK, but not Smad2, in a manner correlating with
increasing metastatic potential (Figure 3a). Importantly, the
improved coupling of TGF-β to p38 MAPK activation in malig-
nant metastatic Ca1a cells correlated with a marked upregula-
tion of FAK expression as compared with their premetastatic
counterparts (Figure 3a). These findings are consistent with
the notion that the acquisition of metastasis by breast cancer
cells coincides with their elevated expression of FAK, which
enhances p38 MAPK activation by TGF-β and its pro-meta-
static activities.
To investigate the merits of this supposition, we compared the
ability of control and FAK-deficient metastatic breast cancer
cells to activate Smad2/3 and p38 MAPK in response to TGF-
β. We found that FAK deficiency dramatically not only
decreased basal p38 MAPK phosphorylation, but also com-
pletely abrogated the ability of TGF-β to activate p38 MAPK
(Figure 3b). Interestingly, in contrast to what we observed in
Figure 2
Focal adhesion kinase (FAK) is critically involved in normal mammary epithelial cell (MEC) migration and p38 MAPK signaling stimulated by trans-forming growth factor (TGF)-β
forming growth factor (TGF)-β. (a) Control (i.e., scram) and FAK-deficient (shFAK) NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for varying 
times as indicated, at which point whole-cell extracts were prepared and immunoblotted with phospho-specific antibodies against Smad2 (p-
smad2), Smad3 (p-smad3), or p38 MAPK (p-p38) as shown. Immunoblot analysis of total p38 MAPK, Smad2/3, FAK, and β-actin serves as loading 
controls. Data are representative images from a single experiment that was repeated 3 times. (b) Control (i.e., scram) and FAK-deficient (shFAK) 
NMuMG cells were transiently transfected with pSBE-luciferase and pCMV-β-gal cDNAs, and subsequently were stimulated with TGF-β1 (5 ng/ml) 
for 18 hours. Afterward, luciferase and β-gal activities present in detergent-solubilized cell extracts were measured. Data are expressed as the mean 
(± SEM) ratios of luciferase:β-gal activity observed in three independent experiments completed in triplicate. (c) Fluorescently labeled phalloidin 
staining showed the formation of F-actin stress fibers in control (i.e., scram) NMuMG cells treated for 18 hours with TGF-β1 (5 ng/ml). FAK-defi-
ciency (shFAK) significantly impaired the ability of TGF-β1 to induce stress fibers, as well as disrupted normal actin cytoskeletal architecture. Data 
are representative images from a single experiment that was repeated twice. (d) Control (i.e., scram) and FAK-deficient (shFAK) NMuMG cell migra-
tion into denuded wounds over a 48-hour period in the absence (NS) or presence of either the TβR-I inhibitor, SB-431542 (10 μM, SB) or TGF-β1 
(5 ng/ml). Data depict the mean (± SEM) percentage of wound closure measured in five independent experiments. FAK deficiency inhibited tonic 
and TGF-β1-stimulated NMuMG cell migration. In addition, tonic NMuMG cell migration was inhibited by SB-431542, indicating disruption of auto-
crine TGF-β signaling in wounded cultures (*P < 0.05; **P < 0.005).Page 6 of 16
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/11/5/R68NMuMG cells (Figure 2a and 2b), the coupling of TGF-β to
both Smad2 and Smad3 were also decreased in FAK-defi-
cient 4T1 cells (Figures 3b and 3c). These data stress the
increased dependence of metastatic breast cancer cells on
FAK to facilitate not only noncanonical (p38 MAPK), but also
canonical (Smad2/3) TGF-β signaling (Figure 3).
Previously, we established Src as being essential for the ability
of TGF-β to stimulate p38 MAPK in MECs [19]. To investigate
the role of FAK in this mechanism, we now analyzed the phos-
phorylation and activation status of Src (i.e., phosphorylation
at Y416) in control and FAK-depleted cells, which showed
that FAK deficiency rendered Src hypophosphorylated in 4T1
cells (Figure 4d). Collectively, these findings are the first to
demonstrate the increasing dependence of metastatic breast
cancer cells on the reciprocal activation between FAK and Src
in mediating downstream TGF-β signaling [28].
FAK expression and kinase activity are required for the 
aberrant formation of β3 integrin:TβR-II signaling 
complexes
We next sought to address the mechanism by which FAK facil-
itates oncogenic TGF-β signaling. Previously, we observed β3
integrin to interact aberrantly with TβR-II [19], resulting in the
promotion of MAPK signaling by TGF-β [17,18]. Indeed,
robust quantities of FAK were detected in β3 integrin:TβR-II
Figure 3
Focal adhesion kinase (FAK) is essential in mediating oncogenic signaling by transforming growth factor (TGF)-βi l i i ti  i  i li  y tr sf r i  r th factor (T F)-β. (a) Increased FAK expression cor-
relates with TGF-β1-mediated activation of p38 MAPK in metastatic human breast cancer cells. The human MCF10A mammary carcinoma progres-
sion system (T1k, well differentiated; Ca1h, premalignant; and Ca1a, metastatic) was stimulated with TGF-β1 (5 ng/ml; tgf), or with TGF-β1 (5 ng/ml) 
in combination with epidermal growth factor (50 ng/ml; t/e) for 30 minutes and subsequently analyzed for phosphorylation of p38 MAPK (p-p38) or 
Smad2 (p-smad2), as indicated. Increased FAK expression was noted in metastatic Ca1a cells. Protein loading was monitored by reprobing 
stripped membranes with antibodies against total p38 MAPK (t-p38), total Smad2/3 (t-smad2/3), and β-actin. Data are representative images from 
a single experiment that was repeated twice. (b) Control (i.e., scram) and FAK-deficient (shFAK) 4T1 cells were stimulated with TGF-β1 (5 ng/ml) for 
varying times, as indicated. Afterward, cell extracts were prepared and immunoblotted with phospho-specific antibodies against Smad2 (p-smad2), 
Smad3 (p-smad3), or p38 MAPK (p-P38), as shown. Reprobing stripped membranes with antibodies against total p38 MAPK (t-p38), total Smad2/
3 (t-smad2/3) FAK, and β-actin served as loading controls. Data are representative images from a single experiment that was repeated 3 times. (c) 
Control (i.e., scram) and FAK-deficient (shFAK) 4T1-luciferase cells were transfected with pSBE-renilla luciferase and stimulated with TGF-β1 (5 ng/
ml) before measuring firefly and renilla luciferase activities. Data are expressed as the mean (± SEM) ratios of renilla:firefly luciferase activity 
observed in three independent experiments completed in triplicate. (*P < 0.05; **P < 0.0001). (d) Src phosphorylation (p-Src-Y416) was 
decreased in FAK-depleted (shFAK) 4T1 cells as compared with their control (i.e., scram) counterparts. Immunoblots were stripped and reprobed 
with antibodies against Src (t-Src), FAK, and β-actin as loading controls. Data are representative images from a single experiment that was repeated 
3 times.Page 7 of 16
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press β3 integrin (Figure 4a; [19]). Furthermore, the formation
of β3 integrin:TβR-II complexes was readily induced in
NMuMG cells subsequent to their induction of EMT by TGF-β
(Figure 4b; [19]). However, this same TGF-β treatment proto-
col failed to induce β3 integrin:TβR-II interaction in FAK-
depleted NMuMG cells, as (a) β3 integrin immunocomplexes
isolated from FAK-deficient NMuMG cells no longer included
TβR-II, and (b) TβR-II immunocomplexes no longer included β3
integrin (Figure 4b). Moreover, whereas the formation of β3
integrin:TβR-II complexes was dependent on EMT in NMuMG
cells, these same complexes were observed to form constitu-
tively in 4T1 cells (Figure 4c). Importantly, depleting FAK
expression in 4T1 cells also reduced the interaction between
β3 integrin and TβR-II, as β3 integrin immunocomplexes iso-
lated from FAK-deficient 4T1 cells no longer included TβR-II
(Figure 4c). The formation of β3 integrin:TβR-II complexes
leads to Src-mediated phosphorylation of TβR-II on Y284,
which coordinates the recruitment and binding of Grb2 to
TβR-II [18]. We now show that FAK deficiency prevented the
Figure 4
Focal adhesion kinase (FAK) activity coordinates the formation of β3 integrin:TβR-II complexes. (a) β3 integrin was immunoprecipitated (β3 I.P.) from 
control (i.e., GFP) or β3 integrin-expressing NMuMG cell extracts, and the resulting immunocomplexes were immunoblotted with antibodies against 
TβR-II and FAK, as indicated. Direct immunoblot analysis of an aliquot of the prepared cell extracts (Input) served to monitor the total levels of TβR-II, 
β3 integrin, and β-actin. Data are representative images from a single experiment that was repeated 3 times and show that FAK was present in β3 
integrin:TβR-II complexes. (b) β3 integrin (β3 I.P.) or TβR-II (TβR-II I.P.) were immunoprecipitated from control (i.e., scram) and FAK-deficient (shFAK) 
NMuMG cell extracts before (pre-EMT) or after (post-EMT) their induction of EMT by TGF-β1 (5 ng/ml, 24 hours), and the resulting immunocom-
plexes were reciprocally immunoblotted for β3 integrin or TβR-II. Direct immunoblot analysis of an aliquot of the prepared cell extracts (Input) served 
to monitor the total levels of TβR-II, β3 integrin, FAK, and β-actin. (c) β3 integrin was immunoprecipitated (β3 I.P.) from control (scram) and FAK-defi-
cient (shFAK) 4T1 cell extracts, and the resulting immunocomplexes were immunoblotted for TβR-II and FAK, as indicated. Direct immunoblot analy-
sis of an aliquot of the prepared cell extracts (Input) served to monitor the total levels of FAK, TβR-II, and β-actin. Data are representative images 
from a single experiment that was repeated 4 times and show that FAK deficiency inhibits the formation of β3 integrin:TβR-II complexes. (d) Grb2 
was immunoprecipitated (Grb2 I.P.) from vector control (cntrl), TβR-II- (TβR-II), and FAK-deficient and TβR-II-expressing (TβR-II/shFAK) 4T1 cell 
extracts, and the resulting immunocomplexes were immunoblotted for TβR-II, FAK, and Grb2, as indicated. Direct immunoblot analysis of an aliquot 
of the prepared cell extracts (Input) served to monitor the total levels of TβR-II, FAK, and β-actin. Data are representative images from a single exper-
iment that was repeated 3 times and show that FAK deficiency inhibits the interaction between Grb2 and TβR-II. (e) β3 integrin was immunoprecipi-
tated (β3 I.P.) from unstimulated (NS) cell extracts derived from 4T1 cells and cells incubated for 18 hours with the FAK inhibitors PF-562271 (271) 
or PF-573228 (228), as indicated. The resulting immunocomplexes were immunoblotted for TβR-II. Direct immunoblot analysis of an aliquot of the 
prepared cell extracts (Input) served to monitor the levels of FAK phosphorylated at Y397 (pFAK), total FAK (tFAK), TβR-II, and β-actin. Data are rep-
resentative images from a single experiment that was repeated 3 times and show that FAK PTK activity is required for the formation of β3 
integrin:TβR-II complexes.Page 8 of 16
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plexes isolated from FAK-depleted 4T1 cells no longer
included TβR-II (Figure 4d).
Finally, we found that the PTK activity of FAK was absolutely
required for the formation of β3 integrin:TβR-II complexes, as
treatment of 4T1 cells with an effective concentration (see
Additional data file 3d) of FAK inhibitors (PF-562271 and PF-
573228) similarly abolished the interaction between β3
integrin and TβR-II (Figure 4e). Taken together, these findings
demonstrate that FAK expression and activity are required for
the formation of β3 integrin:TβR-II:Grb2 complexes (Figure 4)
and, consequently, for the initiation of aberrant oncogenic
TGF-β signaling (Figure 3).
FAK is critically involved in TGF-β-stimulated invasion of 
malignant MECs
To elucidate the significance of FAK in mediating oncogenic
TGF-β signaling, we first compared the ability of TGF-β to
induce EMT in control and FAK-deficient 4T1 cells. Figure 5a
shows that FAK-depleted 4T1 cells failed to undergo the char-
acteristic cell scattering that is normally associated with the
induction of EMT (Figure 5a). In contrast to control cells, FAK-
depleted 4T1 cells maintained cell-cell junctions that, in many
respects, reflect the cortical actin patterns observed in unstim-
ulated normal MECs (Figure 1a). We corroborated these mor-
phologic findings by examining the differential expression of
several genes associated with EMT in control and FAK-defi-
cient 4T1 cells before and after their treatment with TGF-β. In
doing so, we observed TGF-β administration to reduce dra-
matically the 4T1 cell expression of E-cadherin (E-cad) protein
and to increase the amount of PAI-1 protein in the conditioned
media (Figure 5b). Importantly, both TGF-β-dependent
responses were lost in 4T1 cells depleted for FAK expression
(Figure 5b).
More thoroughly to characterize the role of FAK in TGF-β1-
induced EMT, we also examined a panel of EMT markers by
real-time PCR. As shown in Figure 5c, the downregulation of
the epithelial markers E-cad and cytokeratin-19, which are
characteristic features of EMT induced by TGF-β, was effec-
tively prevented by depletion of FAK. Most interestingly, with
the exception of PAI-1, the upregulation of mesenchymal mark-
ers was not appreciably affected by FAK deficiency (Figure
5c). The maintenance of an epithelial gene-expression profile
is consistent with the epithelial morphology of FAK-depleted
4T1 cells (Figure 5a), and is further supported by a recent
study in hepatocytes showing that the expression of a domi-
nant-negative FAK prevents the downregulation of epithelial
gene expression without affecting the ability of TGF-β to
induce mesenchymal gene expression [29].
Consistent with the switch of TGF-β from a tumor suppressor
to a tumor promoter, we and others observed TGF-β to induce
the invasion of breast cancer cells, a result that is not recapit-
ulated by normal MECs [18,30]. We therefore monitored the
ability of control and FAK-deficient 4T1 cells to invade syn-
thetic basement membranes in response to TGF-β. Figure 5d
shows that whereas FAK-deficiency failed to affect the inva-
sion of 4T1 cells induced by a nonspecific serum stimulus, this
same cellular condition abrogated the ability of 4T1 cells to
undergo enhanced invasion in response to TGF-β (Figure 5d).
Previous findings by our laboratory established a model
whereby constitutive expression of TβR-II increases the inva-
sion of 4T1 cells [18]. Importantly, depletion of FAK in "hyper-
metastatic" 4T1-TβR-II cells actually reversed the affects of
TβR-II expression, as TβR-II-shFAK cells completely failed to
invade to a serum stimulus (Figure 5e). Taken together, these
data identify FAK as an essential player in mediating carci-
noma cell EMT and invasion induced specifically by TGF-β.
FAK inhibition reduces breast cancer growth and 
metastasis
Recent data suggest that FAK is required for mammary tumor
progression and metastasis [10,11,15]; however, the precise
mechanisms whereby FAK promotes tumor progression
remain to be elucidated. Although FAK depletion had no affect
on primary tumor growth (Figure 6a), bioluminescent imaging
of mice bearing 4T1 tumors did show that pulmonary metasta-
sis was reduced significantly upon FAK depletion (Figure 6b).
In accordance with our in vitro findings (Figure 3), immunohis-
tochemistry of 4T1 tumors demonstrated a dramatic decrease
in the phosphorylation of p38 MAPK and Smad2 with FAK
depletion (Figure 6c). Thus, these findings suggest that FAK
plays a critical role in regulating TGF-β signaling and the
metastasis of mammary tumors in mice.
In contrast to tumor cell depletion of FAK, therapeutic admin-
istration of the FAK inhibitor, PF-562271, significantly
decreased the growth of primary 4T1 tumors (Figure 6d). The
reduction in 4T1 tumor growth likely reflects diminished PTK
activity of FAK, as tumors from biopsies of mice treated with
PF-562271 possessed significantly less phosphorylated FAK
as compared with their vehicle-treated counterparts (see
Additional data file 3e). Moreover, PF-562271 decreased pul-
monary metastasis in a fashion highly reminiscent of that
observed in tumors depleted in FAK expression (Figure 6e).
The difference in primary tumor growth between FAK-depleted
cells (Figure 6a) and systemic FAK inhibition by PF-562271
(Figure 6d) suggests that FAK plays an important role in gov-
erning the composition or activity or both of nontumor cells in
the tumor microenvironment, including the potential recruit-
ment of systemic cell populations required for optimal mam-
mary tumor growth and progression. Accordingly, we
observed 4T1 tumors to exhibit strong staining for the macro-
phage marker F4/80, a result that was not recapitulated with
PF-562271 administration (Figure 6f). Thus, we show for the
first time that, in addition to the critical roles FAK plays in
directing carcinoma cell function and behavior, the PTK activ-
ity of FAK is also clearly required for regulating innate immunityPage 9 of 16
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mammary tumors.
We next used the 4T1-TβR-II model to access the specific role
of FAK in TGF-β-driven breast cancer metastasis. As shown in
Figure 7a, FAK depletion had no effect on primary tumor
growth of 4T1-TβR-II cells. Furthermore, although FAK-defi-
cient 4T1-TβR-II cells were still highly metastatic, FAK deple-
tion did significantly decrease the immediate pulmonary
dissemination of 4T1-TβR-II cells (Figure 7b). These data sug-
gest that FAK selectively regulates the initial steps of tumor
cell dissemination stimulated by TGF-β, a result that is consist-
ent with our findings of the requirement of FAK in (a) mediating
EMT stimulated by TGF-β (Figure 5) and (b) preventing pri-
mary colonization of breast cancer cells in the lung (Figure 6b,
weeks 2 to 3), but not their secondary outgrowth (Figure 6b,
weeks 3 to 4). In addition, we found no differences in the ability
of control or FAK-deficient 4T1 cells to colonize the lungs after
their injection into the tail vein of Balb/C mice (see Additional
data file 4c). Taken together, these data suggest that the cou-
pling of TGF-β to FAK promotes the initial invasion and exit of
breast cancer cells from the primary tumor site. Moreover, and
similar to control 4T1 cells, PF-562271 administration begin-
ning 1 week after engraftment of 4T1-TβR-II cells significantly
Figure 5
Focal adhesion kinase (FAK) is critical for TGF-β stimulation of invasion in malignant mammary epithelial cells (MECs). (a) Fluorescent-conjugated 
phalloidin staining of control (i.e., scram) and FAK-deficient (shFAK) 4T1 cells indicated that FAK deficiency (shFAK) preserved cortical actin stain-
ing at cell-cell borders with TGF-β1 (5 ng/ml) stimulation. Data are representative images from a single experiment that was repeated twice. (b) Con-
trol (i.e., scram) and FAK-deficient (shFAK) 4T1 cells were stimulated with TGF-β1 (5 ng/ml) for varying times, as indicated. Afterward, cell extracts or 
supernatants were immunoblotted with antibodies against E-cadherin (E-cad) or plasminogen activator inhibitor-1 (PAI-1), respectively. Immunoblot-
ting for β-actin served as a loading control. Data are representative images from a single experiment that was repeated twice and show that FAK 
deficiency inhibited epithelial-mesenchymal transition (EMT) stimulated by TGF-β. (c) Control (i.e., scram) and FAK-depleted (shFAK) 4T1 cells were 
stimulated with TGF-β1 (5 ng/ml) for 24 hours. Afterward, the downregulation of the epithelial markers E-Cad and cytokeratin-19 (CK19), and the 
upregulation of the mesenchymal markers, PAI-1, matrix metalloproteinase 9 (MMP9), cyclooxygenase-2 (Cox2), and β3 integrin (Beta3) were ana-
lyzed with semiquantitative real-time PCR. Data are expressed as the mean fold change (± SEM) in gene expression relative to unstimulated cells 
observed in at least three independent experiments (*P < 0.05). (d) FAK deficiency specifically inhibited cell invasion induced by TGF-β. Data are 
the mean (± SEM) invasion of each 4T1 cell line normalized to serum-stimulated invasion observed in three independent experiments completed in 
triplicate. (*P < 0.05; **P < 0.005). (e) FAK deficiency reversed TβR-II-mediated cellular invasion. Data are expressed as the mean (± SEM) invasion 
of each 4T1 cell line relative to its unstimulated counterpart (NS) observed in three independent experiments completed in triplicate. (*P < 0.05; **P 
< 0.001).Page 10 of 16
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Figure 6
Focal adhesion kinase (FAK) mediates tumor cell autonomous-driven metastasis and systemically driven mammary tumor growth. (a) Control (i.e., 
scram) and FAK-deficient (shFAK) 4T1 cells were engrafted onto the mammary fat pads of 6-week-old Balb/C mice. Data are expressed as the mean 
(± SEM) tumor volumes (n = 5) measured at the indicated time points after engraftment. (b) FAK-deficient 4T1 tumors displayed significantly 
decreased pulmonary metastasis. Data are the mean (± SEM) pulmonary area flux units detected in Balb/C mice (n = 5) imaged at the indicated time 
points after engraftment (*P < 0.05). Shown are representative mice engrafted with control (i.e., scram) and FAK-deficient (shFAK) 4T1 cells (inset). 
(c) Immunostaining primary tumor sections with phospho-specific antibodies against p38 MAPK (p-p38) or Smad2 (p-smad2) showed intense 
nuclear localization of phosphorylated p38 MAPK at the invasive front of control (i.e., scram) tumors (black arrows). Tumors derived from FAK-defi-
cient 4T1 cells exhibit significantly reduced phosphorylation and nuclear accumulation of p38 MAPK (black arrows). Similarly, abundant phosphor-
ylation of Smad2 (p-smad2) was readily detected near the invasive front of control (i.e., scram) 4T1 tumors (right of the line), but not in tumors arising 
from their FAK-deficient (shFAK) counterparts. (d) 4T1 cells were engrafted onto the mammary fat pads of 6-week-old Balb/C mice. One week after 
engraftment, the mice were left untreated (NS) or treated with the FAK inhibitor PF-562271 (PF-271; 50 mg/kg/day) for the duration of the experi-
ment. Data are expressed as the mean (± SEM) tumor volumes (n = 5) measured at the indicated time points after engraftment (*P < 0.05; **P < 
0.005). (e) Mice treated with PF-562271 as in panel (d) displayed significantly decreased pulmonary metastasis. Data are expressed as the mean (± 
SEM) pulmonary area flux units detected in Balb/C mice (n = 5) imaged at the indicated time points after engraftment (**P < 0.005). Shown are rep-
resentative untreated (NS) or PF-562271 (PF-271)-treated mice (inset). (f) Control (NS) 4T1 mammary fat-pad tumors displayed a high degree of 
macrophage infiltration, as demonstrated by immunostaining for the F4/80 antigen. Macrophage infiltration was greatly reduced in tumor-bearing 
mice treated with PF-562271 (PF-271).
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treatment protocol had no effect on the subsequent metasta-
sis of 4T1-TβR-II cells (Figure 7d).
Collectively, these findings provide the first evidence that FAK
activity can be inhibited chemotherapeutically as an effective
two-pronged approach to reduce the growth and metastasis
of breast cancers. Moreover, these results also show that
amplified TGF-β signaling in breast cancer cells is capable of
driving early tumor cell dissemination from the primary mam-
mary tumor.
Discussion
TGF-β is a principal player involved in suppressing mammary
tumorigenesis by maintaining the composition of normal MEC
microenvironments through its ability to inhibit the proliferation
and survival of normal MECs [31,32]. In stark contrast, mam-
mary tumorigenesis has evolved a variety of mechanisms capa-
ble of subverting the tumor-suppressing functions of TGF-β
and of conferring oncogenic and metastatic properties on this
multifunctional cytokine [30,33]. Along these lines, elevated
FAK expression is observed in a variety of human cancers,
including those of the lung [34], uterus [35], mouth [36], thy-
roid [37], colon [38], ovary [39], and, most notably, the breast
[38,40,41]. Thus, upregulated expression of FAK is associ-
ated with the development and progression of human cancers.
Accordingly, numerous models have shown that rendering
breast cancer cells deficient in FAK inhibits their progression
and the acquisition of metastatic phenotypes [10,14,15]. The
data shown herein identify FAK as an essential member of
oncogenic β3 integrin:TβR-II signaling complexes. FAK-defi-
ciency not only prevented the physical interaction between β3
integrin and TβR-II, but also abrogated oncogenic signaling by
TGF-β and its ability to induce EMT, invasion, and systemic
dissemination of breast cancer cells. Thus, FAK is a critical
effector of metastasis stimulated by TGF-β in developing and
progressing mammary tumors.
Recent data also suggest that FAK mediates in vitro TGF-β
signaling and gene expression in fibroblasts [42], hepatocytes
[29], and mesangial cells [43], further highlighting the biologic
importance of this signaling and scaffolding molecule.
Figure 7
TβR-II-dependent, early primary tumor cell dissemination is dependent on focal adhesion kinase (FAK). (a) TβR-II (TβR-II)- or TβR-II-expressing/FAK 
deficient (TβR-II-shFAK) 4T1 cells were engrafted onto the mammary fat pads of 6-week-old Balb/C mice. Data are expressed as the mean (± SEM) 
tumor volumes (n = 5) measured at the indicated time points after engraftment. (b) FAK-deficient TβR-II tumors displayed significantly decreased pri-
mary tumor dissemination 1 week after tumor cell engraftment. Data are expressed as the mean (± SEM) pulmonary area flux units detected in Balb/
C mice (n = 5) imaged at the indicated time points after engraftment (*P < 0.05). (c) One week after engraftment, 4T1-TβR-II tumor-bearing mice 
were left untreated (NS) or treated with the FAK inhibitor PF-562271 (PF-271; 50 mg/kg/day) for the duration of the experiment, as described in Fig-
ure 6c and 6d. Data are expressed as the mean (± SEM) tumor volumes (n = 5) measured at the indicated time points after engraftment (*P < 0.05; 
**P < 0.005). (d) Mice bearing 4T1-TβR-II tumors that were treated with PF-562271, as in panel (c) (n = 5) displayed similar pulmonary metastasis 
compared with controls. Data are expressed as the mean (± SEM) pulmonary area flux units detected in Balb/C mice (n = 5) imaged at the indicated 
time points after engraftment.Page 12 of 16
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inhibitors of FAK (i.e., PF-562271 and PF-573228), we spe-
cifically defined the PTK activity of FAK as being essential for
mediating the formation of β3 integrin:TβR-II complexes. More-
over, therapeutic administration of PF-562271 reduced pul-
monary metastasis in a manner reminiscent of that observed
with total FAK depletion, suggesting that the PTK activity of
FAK, as opposed to its scaffolding function, is the major
aspect of the this molecule required for cellular metastasis. A
clinically relevant finding of our study was that FAK clearly is
required for the initiation of TGF-β signaling and its stimulation
of EMT and invasion. More important, we showed for the first
time that amplified TGF-β signaling through increased TβR-II
expression [18] was sufficient in subverting the metastatic
benefit of FAK chemotherapies, by using the same treatment
protocol that was sufficient in reducing the metastasis of wild-
type breast cancer cells. These data suggest that TGF-β
drives cellular dissemination from the primary tumor and early
metastatic lesion formation, processes that absolutely require
FAK expression and PTK activity. This conclusion is wholly
supported by recent independent studies showing that both
FAK and TGF-β signaling are critically involved in these early
steps of tumor dissemination, but not metastatic outgrowth
[44,45].
Mechanistically, we showed that FAK becomes activated with
TGF-β-mediated induction of EMT, a process that is depend-
ent on Src and β3 integrin (Figure 1[46]). Moreover, we
present data to suggest that TGF-β-stimulated upregulation of
β3 integrin acts as a negative-feedback mechanism regulating
the transcription not only of itself, but also that of FAK. Thus,
these and our previous findings indicate that the transactiva-
tion of FAK and Src facilitates the interaction between β3
integrin and TβR-II, leading to phosphorylation of TβR-II at
Y284 [18] and its interaction with Grb-2 [17]. Indeed, the for-
mation of integrin:TβR-II complexes, as well as other signaling
modules involving TGF-β receptors [47,48], appears to be
governed by a variety of protein-protein interactions and post-
translational modifications.
Overall, the formation of these aberrant complexes function to
promote the oncogenic activities of TGF-β in developing and
progressing breast cancers. Our findings also point to the
importance of thoroughly defining the composition and func-
tion of these TGF-β signaling complexes in normal and meta-
static cells. As such, we show here that β3 integrin:TβR-II
complexes are present constitutively in metastatic MECs, but
only form in normal MECs upon their induction of EMT.
Accordingly, disruption of FAK decreases TGF-β-induced
Smad2/3 activation and completely abrogates p38 MAPK
stimulation in metastatic MECs, whereas FAK depletion in nor-
mal MECs only partially blocks TGF-β-induced p38 MAPK
activation with no affect on Smad2/3 activity.
Clearly, these data demonstrate the increased dependence of
metastatic breast cancer cells on FAK to facilitate oncogenic
TGF-β signaling. Moreover, they suggest that targeting FAK
and other constituents of the focal adhesion complex, such as
integrins, p130Cas, talin, or paxillin, holds the potential to inac-
tivate specifically the oncogenic activities of TGF-β in malig-
nant MECs. Moreover, our findings suggest that the
development and use of such a chemotherapeutic regimen
would have little impact on altering the tumor-suppressor func-
tion of TGF-β in normal MECs.
A scientifically and medically important finding of this study
was the difference noted between tumor cell depletion of FAK
and systemic FAK inhibition by using PF-562271. We demon-
strated a drastic diminution in primary tumor growth in control
and TβR-II-expressing 4T1 cells after PF-562271 treatment.
These data point to an important role for FAK in regulating the
composition and behavior of breast cancer stroma, particularly
the recruitment of bone marrow-derived and other systemic
immune cells whose presence is critical for mammary tumori-
genesis [49]. To this end, we show a drastic reduction in
tumor-infiltrating macrophages with FAK inhibition. Although a
full characterization of the role for FAK in governing mammary
stromal function clearly is warranted and currently is ongoing
in our laboratory, the data presented here undoubtedly identify
a novel tumor microenvironmental function for FAK that has yet
to be fully appreciated.
Conclusions
In summary, we demonstrate that FAK is activated upon TGF-
β-mediated induction of EMT in a manner that requires β3
integrin and Src, and that the PTK activity of FAK is required
for the physical linkage between β3 integrin and TβR-II, thereby
generating the formation of oncogenic TGF-β signaling com-
plexes. Indeed, our findings establish FAK as an essential
player that facilitates the oncogenic conversion of TGF-β in
developing and progressing mammary tumors, leading to their
acquisition of invasive and metastatic phenotypes in response
to TGF-β. Finally, we provide compelling evidence that inhibit-
ing the PTK activity of FAK or its expression is sufficient to
reduce the overall metastatic burden of highly aggressive
breast cancers, and more specifically, that amplified TGF-β
signaling in these same tumors is capable of driving the earli-
est steps of primary tumor metastasis, processes that are crit-
ically dependent on FAK.
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A TIFF file containing a figure showing that FAK 
deficiency decreases the growth rate and inhibits 
cytostasis mediated by TGF-β in normal MECs. (a) 
Control (i.e., scram) and FAK-deficient (shFAK) NMuMG 
and 4T1 cells were cultured in full growth media for 48 
hours before addition of [3H]thymidine. Afterward, the 
extent of [3H]thymidine incorporation into cellular DNA 
was determined with scintillation counting, which 
showed that FAK deficiency significantly decreased the 
basal growth rate of NMuMG but not 4T1 cells. Data are 
expressed as the mean (± SEM) rates of DNA synthesis 
of each cell line relative to the corresponding controls 
observed in three independent experiments (*P < 0.05). 
(b) Control (i.e., scram) and FAK-deficient NMuMG 
(squares) and 4T1 (circles) cells were incubated for 48 
hours in the absence or in the presence of increasing 
concentrations of TGF-β1, as indicated. Incorporation of 
[3H]thymidine into cellular DNA was determined as 
described earlier. Data are expressed as the mean (± 
SEM) rates of DNA synthesis relative to untreated 





A JPEG file containing a figure characterizing the use of 
small-molecule inhibitors of FAK in NMuMG and 4T1 
cells. (a) NMuMG cells were stimulated for 18 hours with 
TGF-β1 in the presence of the indicated concentrations 
of the FAK inhibitor PF-573228 (PF-228). Cells were 
subsequently lysed, and FAK autophosphorylation at 
Y397 was assayed. β-Actin serves as a loading control. 
(b) NMuMG cells were serum deprived for 4 hours in the 
absence or presence of the FAK inhibitor PF271 or 
PF228 (1 μM), and subsequently were stimulated with 
TGF-β1 (5 ng/ml) for 30 minutes. Cells were lysed and 
assayed for FAK autophosphorylation at Y397. The 
membrane was stripped and reprobed for total FAK 
(tFAK) as a loading control. (c) Bright-field images of 
NMuMG cells under unstimulated (NS) conditions or 
those treated with TGF-β1 (5 ng/ml), PF-573228 (1 μM), 
or both agents for 24 hours. (d) 4T1 cells were 
incubated in the presence of increasing concentrations 
of the FAK inhibitor PF-562271 for 18 hours, at which 
point, the cells were lysed, and FAK autophosphorylation 
at Y397 was assayed. Membranes were stripped and 
reprobed for total FAK (tFAK) and β-actin as loading 
controls. (e) Mice bearing primary fat pad 4T1 tumors 
were left untreated (NS) or treated with PF-562271 (PF-
271; 50 mg/kg/day). Four hours after the final treatment, 
the tumors were excised, and histologic sections were 
stained with antibodies specific for FAK 
autophosphorylation at Y397.
See http://www.biomedcentral.com/content/
supplementary/bcr2360-S3.JPEGPage 14 of 16
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